Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)

NCT03373877 is registered in ClinicalTrials.gov with Samus Therapeutics, Inc. as lead sponsor.

NCT NCT03373877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03373877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Lead sponsor
Samus Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 24, 2018
Completion date
March 10, 2020
Enrollment
4 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis